Issue 4, 2024

AiZynth impact on medicinal chemistry practice at AstraZeneca

Abstract

AstraZeneca chemists have been using the AI retrosynthesis tool AiZynth for three years. In this article, we present seven examples of how medicinal chemists using AiZynth positively impacted their drug discovery programmes. These programmes run the gamut from early-stage hit confirmation to late-stage route optimisation efforts. We also discuss the different use cases for which AI retrosynthesis tools are best suited.

Graphical abstract: AiZynth impact on medicinal chemistry practice at AstraZeneca

Supplementary files

Article information

Article type
Opinion
Submitted
20 Nov 2023
Accepted
15 Feb 2024
First published
16 Feb 2024

RSC Med. Chem., 2024,15, 1085-1095

AiZynth impact on medicinal chemistry practice at AstraZeneca

J. D. Shields, R. Howells, G. Lamont, Y. Leilei, A. Madin, C. E. Reimann, H. Rezaei, T. Reuillon, B. Smith, C. Thomson, Y. Zheng and R. E. Ziegler, RSC Med. Chem., 2024, 15, 1085 DOI: 10.1039/D3MD00651D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements